Sanofi SA

FR

SASY

Health Care

47.15 ₽

Current price

Buy
47.15 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    374 / 1328

  • Position in country

    295 / 834

  • Net income margin, %

    7.9

    2.8

  • EBITDA margin, %

    33.5

    10.8

  • Debt to Equity, %

    24.8

    19.2

  • Intangible assets and goodwill, %

    58.2

    3.6

  • Revenue CAGR 3Y, %

    7.5

    8.5

  • Revenue Y, % chg

    5.9

    0.5

  • P/E

    20

    22.7

  • P/BV

    1.4

    1.5

  • P/S

    2.3

    2.3

  • EV/S

    2.5

    2.4

  • EV/EBITDA

    7.9

    7.4

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    26.5

    51.3

  • Forward P/E

    10.6

    15.6

  • Dividend Yield, %

    4.3

    1.7

  • Forward Dividend Yield, %

    4.5

    0.2

  • Expected dividend per share

    2

    0

  • Payout Ratio, %

    163.9

    30.3

  • Dividend Ex Date

    2024-05-09

Get an analytical review of this company

Competitors

Ranks

  • Ipsen SA

    00%

  • Novo Nordisk A/S

    00%

  • Sanofi SA

    00%

  • AstraZeneca PLC

    00%

  • Vetoquinol SA

    00%

  • Eli Lilly and Co

    00%

  • Virbac SA

    00%

  • Novartis AG

    00%

  • Johnson & Johnson

    00%

  • Merck & Co Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    France

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Pharmaceuticals

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    117293.4

  • Ticker

    SNY.OQ

  • ISIN

    US80105N1054

  • IPO date

    2002-07-01

  • Availability on Russian exchanges

    Yes

  • Reporting for

    2024-02-23

  • Date fact. publication of reports

    2023-12-31

Company Description

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.